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Background:  Elderly patients comprise a large portion of heart failure (HF) patients. However, there are limited data on the effectiveness of 
cardiac resynchronization therapy with defibrillator (CRT-D) among patients in this population.
Methods:  Cox proportional hazards regression modeling was used to assess the benefit of CRT-D compared with ICD-only therapy in reducing the 
risk of HF or death by age categories (<60 [n=548], 60-74 [n=941], and ≥ 75 [n=331] years) among 1820 patients enrolled in MADIT-CRT.
Results:  In multivariate analysis, a significant CRT-D benefit was shown in ages 60-74, and ≥ 75 years (HR=0.57, p<0.001 and HR=0.59, p=0.01, 
respectively), whereas no significant benefit of CRT-D was demonstrated among patients <60 years (HR=0.81, p=0.30; p-value for treatment-by-age 
interactions >0.10). Consistently, Kaplan-Meier analysis showed that the 3-year cumulative probability of HF or death among CRT-D treated patients 
was significantly lower than among ICD patients in the both age-groups ≥60 years, and similar to ICD patients in the age group <60 years (Fig.).
Adverse events within 90 days of CRT-D implantation was not significant (17%, 16%, and 12%, in <60, 60-74, and ≥ 75 years, respectively; p=0.42).
Conclusion: Treatment with CRT-D is associated with a significant benefit in patients ≥60 years and among elderly patients >75 years of age, 
without an increase adverse events in the older age-group. The clinical benefit of CRT-D appears to be attenuated in lower-risk younger patients. 
